Effectiveness of Convalescent Plasma Therapy in Treating COVID-19: an Evidence-based Case Report

Mira Yulianti, Christian Johan, Gurmeet Singh, Eric Daniel Tenda, Herikurniawan Herikurniawan, I Putu Eka Krisnha Wijaya


Background: Convalescent plasma is a potentially beneficial, tolerable, and available additional treatment option for COVID-19. This study aims to evaluate whether the administration of convalescent plasma therapy leads to improved clinical outcomes in COVID-19 patients compared to standard medical therapy. Methods: We conducted a search of Pubmed, Cochrane, and EBSCO for studies assessing the clinical question using inclusion and exclusion criteria. Selected studies were critically appraised, and the results were summarized. Results: A meta-analysis of 10 randomized clinical trials (RCTs), an RCT, a case-control clinical study were selected and assessed. Only the case-control clinical study showed that convalescent plasma administration improved the clinical outcomes of patients with COVID-19, including all-cause mortality, hospital length of stay, and the need for mechanical ventilation. On the contrary, the other two studies of a higher level of evidence showed no significant clinical outcome improvement with convalescent plasma therapy. Conclusion: The effectiveness of convalescent plasma therapy in improving clinical outcomes of patients with COVID-19 was still inconclusive due to several study limitations and other possible causes.


convalescent plasma; coronavirus; COVID-19; SARS-CoV-2


Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol. 2020;92:1475–83. doi: 10.1002/jmv.25961

Burhan E, Susanto AD, Nasution SA, et al. Pedoman tatalaksana COVID-19. 3rd ed. In: Burhan E, Susanto AD, Isbaniah F, et al., editor. Jakarta: PDPI, PERKI, PAPDI, PERDATIN, IDAI, IDAI; 2020.

Zuo Z, Wu T, Pan L, et al. Modalities and mechanisms of treatment for Coronavirus disease 2019. Front Pharmacol. 2021;11:1–19. doi: 10.3389/fphar.2020.583914

Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280.e8. doi: 10.1016/j.cell.2020.02.052

Franchini M, Liumbruno GM. Convalescent plasma for the treatment of severe COVID-19. Biol Targets Ther. 2021;15:31–8. doi: 10.2147/btt.s272063

Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev [Internet]. 2020;19:102554. Available from: https://doi.org/10.1016/j.autrev.2020.102554 doi: 10.1016/j.autrev.2020.102554

Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130:2757–65. doi: 10.1172/JCI138745

Pérez-Cameo C, Marín-Lahoz J. Serosurveys and convalescent plasma in COVID-19. E Clinical Medicine. 2020;23:10–1. doi: 10.1016/j.eclinm.2020.100370

Atal S, Fatima Z. IL-6 Inhibitors in the treatment of serious COVID-19: A promising therapy? Pharmaceut Med [Internet]. 2020;34:223–31. Available from: https://doi.org/10.1007/s40290-020-00342-z doi: 10.1007/s40290-020-00342-z

Janiaud P, Axfors C, Schmitt AM, et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA - J Am Med Assoc. 2021;325:1185–95. doi: 10.1001/jama.2021.2747

Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of vonvalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2020;619–29. doi: 10.1056/nejmoa2031304

Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384:610–8. doi: 10.1056/nejmoa2033700

Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening covid-19: a randomized clinical trial. JAMA - J Am Med Assoc. 2020;324:460–70. doi: 10.1001/jama.2020.10044

Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020;371:1–10. doi: 10.1136/bmj.m3939

Balcells ME, Rojas L, Le Corre N, et al. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. PLoS Med. 2021;18:e1003415. doi: 10.1371/journal.pmed.1003415

Abolghasemi H, Eshghi P, Majid A, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study. Transfus Apher Sci. 2020;59(5): 102.

Joyner MJ, Wright RS, Fairweather DL, et al. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. medRxiv. 2020;1–26. doi: 10.1101/2020.05.12.20099879

Joyner MJ, Bruno KA, Klassen SA, et al. Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin Proc. 2020;95:1888–97. doi: 10.1016/j.mayocp.2020.06.028

U.S. National Library of Medicine. Clinicaltrials.gov [Internet]. 2021 [cited 2021 Mar 29]. Available from: https://www.clinicaltrials.gov/ct2/results?recrs=&cond=Covid19&term=convalescent+plasma&cntry=&state=&city=&dist=

Full Text: PDF


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.